Howard Natter, MD
Neurology · Meadowbrook, PANPI 1578529210
Payments from drug & device makers
Across 541 payments — averaging $27.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Biogen$893
- EMD Serono, Inc.$890
- UCB, Inc.$719
- Abbott$628
- Teva Pharmaceuticals USA, Inc.$611
- plus $8K from 54 others
What the payments were for
- Consulting fees$1501%
- Speaking & faculty fees$2512%
- Travel & lodging$1491%
- Food & beverage$11,79195%
- Education$1161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,879 in reported general payments places this provider in the 75th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 76 | $1,150,442 |
| SolirisEculizumab | 26 | $710,062 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 48 | $652,791 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $486,267 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 29 | $442,990 |
| CopaxoneGlatiramer Acetate | 38 | $368,780 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 17 | $291,786 |
| AubagioTeriflunomide | 18 | $263,642 |
| TecfideraDimethyl Fumarate | 28 | $252,699 |
| XyremSodium Oxybate | 15 | $214,475 |
| NuplazidPimavanserin Tartrate | 20 | $116,866 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 13 | $110,813 |
| Dimethyl Fumarate | 48 | $92,553 |
| Glatiramer Acetate | 30 | $71,749 |
| Aimovig AutoinjectorErenumab-Aooe | 65 | $52,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $31 | $1,150,44276 claims |
| AstraZenecaSoliris | $507 | $710,06226 claims |
| CSL BehringPrivigen | $51 | $486,26713 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $611 | $368,78038 claims |
| PfizerPanzyga, Dilantin | $145 | $297,57633 claims |
| SanofiAubagio | $425 | $263,64218 claims |
| BiogenTecfidera | $893 | $252,69928 claims |
| Acadia Pharmaceuticals IncNuplazid | $333 | $116,86620 claims |
| UCB, Inc.Briviact, Neupro | $719 | $58,45630 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $34 | $50,59812 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $185 | $48,869116 claims |
| SK Life Science, Inc.Xcopri | $296 | $33,68431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Meadowbrook
- David WeismanAbington$9.3M
- Amit Bar-OrPhiladelphia$7.7M
- Thomas LeistPhiladelphia$5.8M
- Jan DrappatzPittsburgh$4M
- Lauren ElmanPhiladelphia$3.3M
- David IrwinPhiladelphia$2.5M
- Paula ClemensPittsburgh$2.1M
- Anoopum GuptaPittsburgh$2M
- Daniel KremensPhiladelphia$1.9M
- Frances JensenPhiladelphia$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.